QuidelOrtho cuts 2026 guidance on weak respiratory season, China pricing uncertainty

Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read

Key Changes

• high

  Full-year 2026 revenue guidance narrowed to $2.70-$2.75B (from $2.7-$2.9B), adjusted EPS cut to $1.80-$2.00 (from $2.00-$2.42), and free cash flow reduced to $100-$120M (from $120-$160M) due to Q1 performance and China market disruption.

  Exhibit 99.1 verify on EDGAR →
• high

  Q1 2026 revenue of $620M declined 10.5% year-over-year; Point of Care fell 34% on weaker respiratory season, Labs down 5% (8% constant currency) on China distributor slowdown tied to pending NHSA pricing guidelines and Middle East conflict disruption.

  Exhibit 99.1 verify on EDGAR →
• high

  GAAP net loss of $92M ($1.35 per diluted share) versus adjusted EBITDA of $109M; updated guidance includes expected impact from draft China NHSA IVD pricing guidelines, though final impact cannot be assessed until guidelines are confirmed.

  Exhibit 99.1 verify on EDGAR →